Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose.

Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose. CPT Pharmacometrics Syst Pharmacol. 2021 05; 10(5):428-440.

View in: PubMed

subject areas

Administration, Oral
Animals
Clinical Trials, Phase II as Topic
Dose-Response Relationship, Drug
Drug Evaluation, Preclinical
Humans
Mice
Models, Theoretical
Piperidines
Protein Kinase Inhibitors
Pyridazines
Pyrimidines
Xenograft Model Antitumor Assays

authors with profiles

DAVID SANGHYUN HONG